Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

•Pooled OS/safety data from the pivotal phase II studies of alectinib in ALK+ NSCLC.•Alectinib demonstrated a final pooled median OS of 29.1 months (95% CI 21.3–39.0).•No new or unexpected safety findings were observed.•Alectinib shows robust efficacy and manageable safety in advanced ALK+ NSCLC. A...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2020-01, Vol.139, p.22-27
Hauptverfasser:	Ou, Sai-Hong Ignatius, Gadgeel, Shirish M., Barlesi, Fabrice, Yang, James Chih-Hsin, De Petris, Luigi, Kim, Dong-Wan, Govindan, Ramaswamy, Dingemans, Anne-Marie, Crino, Lucio, Léna, Hervé, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Mitry, Emmanuel, Müller, Barbara, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N., Shaw, Alice T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alectinib ALK Anaplastic Lymphoma Kinase - metabolism Carbazoles - therapeutic use Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - therapy Cellular Biology Female Follow-Up Studies Humans Life Sciences Lung Neoplasms - metabolism Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - therapy Male Medicin och hälsovetenskap NSCLC Overall survival Piperidines - therapeutic use Pooled analysis Prognosis Protein Kinase Inhibitors - therapeutic use Safety Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!